Inhibitors of prenyl transferases

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 557-561

  Sebti, Said ^a   Hamilton, Andrew D ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIMETHYLALLYLTRANSFERASE; GERANYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE; TRANSFERASE INHIBITOR;

APOPTOSIS; CELL CYCLE; ENZYME INHIBITION; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 0030829794     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00011     Document Type: Review

References (57)

1. Zhang FL, Casey PJ: Protein prenylation: Molecular mechanisms and functional consequences. Annual Rev Biochem 1996, 65:241-269.
2. Lerner EC, Hamilton AD, Sebti SM: Inhibition of ras phenylation - a signaling target for novel anti-cancer drug design. Anti-Cancer Drug Design 1997, 12:229-238.
3. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann Rev Pharmacol Toxicol 1997, 37:143-166.
4. Sebti SM, Hamilton AD: Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 1997, 74:103-114.
5. Sebti SM, Hamilton AD: Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. Biochem Soc Trans 1996, 24:692-699.
6. Koblan KS, Kohl NE, Omer CA, Anthony NJ, Conner MW, deSolms SJ, Williams TM, Graham SL, Hartman GD, Oliff A, Gibbs JB: Farnesyltransferase inhibitors: A new class of cancer chemotherapeutics. Biochem Soc Trans 1996, 24:688-692.
7. Qian Y, Sebti SM, Hamilton AD: Farnesyltransferase as a target for anti-cancer drug design. Biopolymers (Pep Sci) 1997, 43:25-41.
8. Cassidy PB, Poulter CD: Transition state analogs for protein farnesyltransferase. J Am Chem Soc 1996, 118:8761-8762.
9. Leonard DM, Shuler KR, Poulter CJ, Eaton SR, Sawyer TK, Hodges JC, Su TZ, Scholten JD, Gowan RC, Sebolt-Leopold JS, Doherty AM: Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem 1997, 40:192-200.
10. Burns CJ, Guitton JD, Baudoin B, Lelievre Y, Duchesne M, Parker F, Fromage N, Commercon A: Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem 1997, 40:1763-1767.
11. Gaon I, Turek TC, Distefano MD: Farnesyl and geranylgeranyl pyrophosphate analogs incorporating benzoylbenzyl ethers: Synthesis and inhibition of yeast protein farnesyltransferase. Tetrahedron Letters 1996, 37:8833-8836.
12. Scholten JD, Zimmerman KK, Oxender MG, Leonard D, Seboltleopold J, Gowan R, Hupe DJ: Synergy between anions and farnesyldiphosphate competitive inhibitors of farnesyl-protein transferase. J Biol Chem 1997, 272:18077-18081.
13. Dinsmore CJ, Williams TM, Hamilton K, Oneill TJ, Rands E, Koblan KS, Kohl NE, Gibbs JB, Graham SL, Hartrnan GD, Oliff AI: Diarylether inhibitors of farnesyl-protein transferase. Bioorganic & Medicinal Chem Ltrs 1997, 7:1345-1348.
14. Ratemi ES, Dolence JM, Poulter CD, Vederas JC: Synthesis of protein farnesyltransferase and protein geranylgeranyltransferase inhibitors: Rapid access to chaetomellic acid A and its analogues. J Organic Chem 1996, 61:6296-6301.
15. Chen XG, Hasuma T, Yano Y, Yoshimata T, Morishima Y, Wang Y, Otani S: Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin. Anticancer Research 1997, 17:2555-2564.
16. Kwon BM, Lee SH, Kim KS, Lee LR, Lee UC, Hong SH, Bok SH: Rhombenone-farnesyl protein transferase inhibitor from the leaves of hedera rhombea bean. Bioorg Med Chem Lett 1997, 7:971-974.
17. Uchida R, Shiomi K, Inokoshi J, Tanaka H, Iwai Y, Omura S: Andrastin D, novel protein farnesyltransferase inhibitor produced by Penicillium sp. FO-3929. J Antibiotics 1996, 49:1278-80.
18. Uchida R, Shiomi K, Inokoshi J, Masuma R, Kawakubo T, Tanaka H, Iwai Y, Omura S: Kurasoins A and B, new protein farnesyltransferase inhibitors produced by Paecilomyces sp. FO-3684. I. Producing strain, fermentation, isolation, and biological activities. J Antibiotics 1996, 49:932-934.
19. Uchida R, Shiomi K, Inokoshi J, Sunazuka T, Tanaka H, Iwai Y, Takayanagi H, Omura S: Andrastins A-C, new protein farnesyltransferase inhibitors produced by Penicillium sp. FO-3929. II. Structure elucidation and biosynthesis. J Antibiotics 1996, 49:418-424.
20. Mathis JR, Poulter CD: Yeast protein farnesyltransferase: A pre steady-state kinetic analysis. Biochemistry 1997, 36:6367-6376.
21. Tschantz WR, Furfine ES, Casey PJ: Substrate binding is required for release of product from mammalian protein farnesyltransferase. J Biol Chem 1997, 272:9989-9993.
22. Stirtan WG, Poulter CD: Yeast protein geranylgeranlytransferase type-I: steady-state kinetics and substrate binding. Biochemistry 1997, 36:4552-4557.
23. Thissen JA, Casey PJ: Kinetics of protein farnesyltransferase: Sigmoidal vs hyperbolic behavior as a function of assay conditions. Anal Biochem 1996, 243:80-85.
24. Yokoyama K, Zimmerman K, Scholten J, Gelb MH: Differential prenyl pyrophosphate binding to mammalian protein geranylgeranyltransferase I and protein farnesyltransferase and its consequence on the specificity of protein prenylation. J Biol Chem 1997, 272:3944-3952.
25. Witter DJ, Poulter CD: Yeast geranylgeranyltransferase type-II: Steady state kinetic studies of the recombinant enzyme. Biochemistry 1996, 35:10454-10463.
26. Qian D, Zhou D, Ju R, Cramer CL, Yang Z: Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control. Plant Cell 1996, 8:2381-2394.
27. Wu CS, Chuang NN: Carboxy-terminal CVLS-sequence-specific protein farnesyltransferase from the eyes of the shrimp Penaeus japonicus: Purification and characterization. J Exp Zool 1996, 275:346-354.
28. Porter JC, Messer A: Genetic mapping of farnesyltransferase alpha(Fnta) to mouse chromosome 8. Mamm Genome 1996, 7:622-623.
29. Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 1997, 275:1800-1804.
30. Del Villar K, Mitsuzawa H, Yang W, Sattler I, Tamanoi F: Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. J Biol Chem 1997, 272:680-687.
31. Fu HW, Moomaw JF, Moomaw CR, Casey PJ: Identification of a cysteine residue essential for activity of protein farnesyltransferase. Cys299 is exposed only upon removal of zinc from the enzyme. J Biol Chem 1996, 271:28541-28548.
32. Zhang FL, Casey PJ: Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. Biochem J 1996, 320:925-932.
33. Huang CC, Casey PJ, Fierke CA: Evidence for a catalytic role of zinc in protein farnesyltransferase. Spectroscopy of Co2+-farnesyltransferase indicates metal coordination of the substrate thiolate. J Biol Chem 1997, 272:20-23.
34. Agarwal R, Mohan RR, Ahmad N, Mukhtar H: Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: Inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization. Molec Carcinogen 1996, 17:13-22.
35. Leitner JW, Kline T, Carel K, Goalstone M, Draznin B: Hyperinsulinemia potentiates activation of p21 Ras by growth factors. Endocrinology 1997, 138:2211-2214.
36. Goalstone ML, Draznin B: Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes. J Biol Chem 1996, 271:27585-27589.
37. Kumar A, Beresini MH, Dhawan P, Mehta KD: Alpha-subunit of farnesyltransferase is phosphorylated in vivo: Effect of protein phosphatase-1 on enzymatic activity. Biochem Biophys Res Comm 1996, 222:445-452.
38. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA: Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 1997, 272:14501-14514.
39. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997, 275:1649-52.
40. Dietrich A, Brazil D, Jensen ON, Meister M, Schrader M, Moomaw JF, Mann M, Illenberger D, Gierschik P: Isoprenylation of the G protein gamma subunit is both necessary and sufficient for beta gamma dimer-mediated stimulation of phospholipase C. Biochemistry 1996, 35:15174-15182.
41. James G, Goldstein JL, Brown MS: Resistance of K-RASB (V12) proteins to farnesyltransferase inhibitors in Rat1 cells. Proceedings of the Nat. Academy of Sciences of the U.S. of Am. 1996, 93:4454-4458.
42. Lerner E, Qian Y, Hamilton AD, Sebti SM: Disruption of oncogenic K-Ras 4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995, 270:26770-26773.
43. Lerner EC, Zhang TT, Knowles D, Qian Y, Hamilton AD, Sebti SM: Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997, 15:1283-1288.
44. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM: Direct demonstration of geranylgeranylation and farnesylation of KI-Ras in vivo. J Biol Chem 1997, 272:14093-14097.
45. Whyte DB, Kirschmeier P, Hockenberry TN, Nunezoliva I, James L, Catino JJ, Bishop WR, Pai JK: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997, 272:14459-14464.
46. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang RM, Bishop WR: Characterization of HA Ras, N-Ras, KI-Ras4A, and KI-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 1997, 272:10232-10239.
47. Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 1994, 14:4193-4202.
48. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ: The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 1997, 272:10608-10615.
49. Lebowitz PF, Du W, Prendergast GC: Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J Biol Chem 1997, 272:16093-16095.
50. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 1997, 272:15591-15594.
51. McGuire T, Qian Y, Hamilton AD, Sebti SM: Platelet derived growth factor receptor ryrosine phosphorylation requires protein geranylgeranylation and not farnesylation. J Biol Chem 1996, 271:27402-27407.
52. Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM: Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 1996, 13:1991-1999.
53. Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G: GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Research 1997, 57:1846-1850.
54. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM: The geranylgeranyltransferase I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21WAF/CIP/SDII in a-p53 independent manner. J Biol Chem 1997, in press.
55. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Research 1997, 57:708-713.
56. Finder JD, Litz JL, Blaskovich MA, McGuire TF, Qian Y, Hamilton AD, Davies P, Sebti SM: Inhibition of protein geranylgeranylation causes a superinduction of nitric oxide synthase-2 by IL-1β in pulmonary artery smooth muscle cells. J Biol Chem 1997, 272:13484-13488.
57. Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, Quarato P, Ferraboschi P, Santaniello E, Paoletti R, Fumagalli R, Corsini A: Pharmacological control of the mevalonate pathway - effect on arterial smooth muscle cell proliferation. J Pharm & Expermental Therapeutics 1997, 281:1144-1153.